A randomized phase II trial of docetaxelor pemetrexed with or without gefitinib in elderly advanced non-small cell lung cancer patients harboring activating EGFR mutation after failure of the therapy as first-line treatment. - A randomized phase II study of continuou gefitinib plus docetaxel or pemetrexed in elderly gefitinib responders (JMTO LC 12-01)

The Japan-Multinational Trial Organization(JMTO)0 个研究点目标入组 60 人开始时间: 2012年4月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients including clients and employee or stuff of the participating medical institution who are involved in planning and conducting this study 2.Patients who relapsed in one year from the last day of adjuvant chemotherapy 3.Active infection (fever of 38.0 degrees centigrade or higher) 4.Patients with past history including acute interstitial pneumonia, pulmonary drug toxicity and radiation pneumonitis treated with corticosteroids 5.Interstitial pneumonia/ Pulmonary fibrosis 6.Patietns with ileus 7.Uncontrollable diarrhea 8.Active double cancer 9.Serious allergy history 10.Patients with refractory gastric ulcer or a duodenal ulcer 11.Uncontrollable massive,pleural effusion or cardiac effusion 12.Systemic administartion of corticosteroids 13.History of docetaxe or pemetrexed therapy 14.serious medical complications (uncontrollable pulmonary disease, heart disease, kidney disease, liver disease) and inappropriate patients for this study judged by the physicians physician

发起方

The Japan-Multinational Trial Organization(JMTO)